Artificial Intelligence in Pharmaceutical

Global Artificial Intelligence in Pharmaceutical Market to Reach US$5.8 Billion by 2030

The global market for Artificial Intelligence in Pharmaceutical estimated at US$1.2 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 30.1% over the analysis period 2024-2030. Hardware, one of the segments analyzed in the report, is expected to record a 31.6% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Software segment is estimated at 27.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$314.5 Million While China is Forecast to Grow at 28.5% CAGR

The Artificial Intelligence in Pharmaceutical market in the U.S. is estimated at US$314.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$873.7 Million by the year 2030 trailing a CAGR of 28.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 27.7% and 25.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 20.8% CAGR.

Global Artificial Intelligence in Pharmaceutical Market – Key Trends & Drivers Summarized

Why Is Artificial Intelligence Becoming a Game-Changer in the Pharmaceutical Industry?
Artificial Intelligence (AI) is rapidly transforming the pharmaceutical industry by reshaping how drugs are discovered, developed, manufactured, and brought to market. As drug development becomes increasingly costly, time-intensive, and data-heavy, AI offers powerful tools to streamline R&D workflows, identify novel drug candidates, and optimize clinical trial design. Traditional pharma models often take over a decade and billions of dollars to bring a single drug to market, with high attrition rates. AI, particularly machine learning (ML) and deep learning, is addressing these inefficiencies by accelerating hit-to-lead identification, predicting compound efficacy and toxicity, and repurposing existing drugs with greater precision and speed.

AI`s ability to analyze vast datasets—ranging from omics data and electronic health records to biomedical literature and molecular libraries—enables a more targeted and hypothesis-driven approach to drug discovery. Pharma companies are leveraging AI to uncover hidden relationships between disease mechanisms and therapeutic pathways, drastically reducing the trial-and-error component of early-stage R&D. Additionally, AI is being deployed in commercial operations to personalize physician outreach, optimize pricing strategies, forecast demand, and improve patient adherence. As pharma transitions toward data-centric innovation models, AI is becoming central to competitive advantage and operational agility.

How Are AI-Driven Platforms Accelerating Drug Discovery and Clinical Development?
AI is significantly compressing timelines in drug discovery through predictive modeling, molecular simulations, and automated high-throughput screening. Deep learning algorithms trained on vast compound datasets can predict biological activity, binding affinity, ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, and off-target effects, allowing researchers to focus on the most promising candidates. Generative AI models are designing entirely new molecular structures with desired properties, while natural language processing (NLP) tools extract actionable insights from scientific literature and clinical trial databases, enriching target validation and hypothesis generation.

In clinical development, AI is transforming trial design and execution. Machine learning models are being used to identify optimal trial sites, predict patient recruitment rates, and select populations most likely to respond to therapy based on genetic or phenotypic data. AI-enabled remote monitoring and real-world data integration are enhancing adaptive trial designs and post-market surveillance, improving both safety assessments and regulatory compliance. These efficiencies not only reduce cost and attrition but also open the door to precision trials that align with personalized medicine paradigms. As AI continues to bridge the gap between discovery and delivery, it is reshaping the pharmaceutical development lifecycle into a faster, more predictive, and patient-centric process.

Where Is Adoption of AI in Pharmaceuticals Accelerating and Which Stakeholders Are Leading the Charge?
AI adoption in the pharmaceutical industry is accelerating across North America, Europe, and Asia-Pacific, with the U.S. leading in terms of investment, partnerships, and AI start-up activity. Global pharma leaders such as Pfizer, Novartis, Roche, AstraZeneca, and Sanofi are actively partnering with AI-first biotech firms and academic institutions to co-develop proprietary algorithms and next-gen drug discovery engines. Major tech players like Google (DeepMind), IBM Watson Health, and NVIDIA are also collaborating with pharma to provide computing infrastructure and AI platforms tailored for biomedical research.

Europe is emerging as a hub for AI-powered pharmaceutical innovation, particularly in the U.K., Germany, and Switzerland, where strong biotech ecosystems and government funding are fueling cross-sector collaboration. Asia-Pacific, led by China and South Korea, is seeing robust growth driven by national AI strategies, population-scale health datasets, and rapidly advancing clinical trial capabilities. Startups specializing in AI for drug discovery, such as BenevolentAI, Insilico Medicine, Recursion, and Atomwise, are gaining traction by offering scalable platforms that integrate cheminformatics, bioinformatics, and predictive analytics. CROs (Contract Research Organizations) and CDMOs (Contract Development and Manufacturing Organizations) are also integrating AI to enhance service offerings across clinical and commercial stages.

What Is Driving the Global Growth of AI in the Pharmaceutical Sector?
The growth in the artificial intelligence in pharmaceutical market is driven by several converging factors, including the escalating cost and complexity of drug development, the explosion of biomedical data, and the shift toward precision medicine. A primary driver is the increasing ability of AI systems to integrate and analyze multidimensional datasets—spanning genomics, proteomics, imaging, EHRs, and market intelligence—to support faster, evidence-based decisions. Regulatory agencies are also showing openness to AI-enabled innovations, with the FDA and EMA providing guidance on real-world data use, algorithm transparency, and digital biomarker validation.

Venture capital investment, M&A activity, and strategic alliances between pharma and AI vendors are accelerating innovation pipelines. The COVID-19 pandemic further validated AI’s role in therapeutic modeling, vaccine development, and epidemiological tracking, reinforcing institutional confidence in AI`s scalability and impact. Cloud computing, improved data interoperability, and federated learning models are also reducing the barriers to AI adoption by enabling secure, large-scale model training across global data silos. As AI becomes embedded in end-to-end pharmaceutical operations, a critical strategic question emerges: Can the pharmaceutical industry fully harness AI to shorten development timelines, reduce failure rates, and bring safer, more effective therapies to patients faster than ever before?

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Pharmaceutical market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Offering (Hardware, Software, Services); Technology (Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method, Other Technologies); Drug Type (Large Molecules, Small Molecules); Application (Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain, Other Applications); End-User (Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

• Absci Corporation
• Anima Biotech
• Antiverse
• Atomwise
• BenevolentAI
• BPGbio
• Cloud Pharmaceuticals
• Deep Genomics
• Exscientia
• Generate Biomedicines
• GNS Healthcare
• Healx
• IBM Watson Health
• Iktos
• Insilico Medicine
• Insitro
• InveniAI
• Isomorphic Labs
• Microsoft Corporation
• Model Medicines

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.